Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Bessent Says U.S. Must Strengthen Supply Chains and Economic Security 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Oil Prices Rebound as Strait of Hormuz Tensions Return After Ship Attack Near Oman 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
Gold Falls Below $4,000 as Strong Dollar and Fed Rate Hike Expectations Weigh on Prices 
Australian Household Spending Rebounds Strongly in May as Travel and Dining Drive Consumer Growth 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Wall Street Ends Mixed as Micron Surges, Apple Drops After Price Hikes 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
